Full Text View
Tabular View
No Study Results Posted
Related Studies
Sulindac and Plant Compounds in Preventing Colon Cancer
This study has been suspended.
First Received: November 1, 1999   Last Updated: February 6, 2009   History of Changes
Sponsored by: Rockefeller University
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00003365
  Purpose

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of sulindac may be an effective way to prevent colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may prevent the development of colon cancer.

PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin, and quercetin in preventing colon cancer.


Condition Intervention
Colorectal Cancer
Dietary Supplement: curcumin
Dietary Supplement: rutin
Drug: quercetin
Drug: sulindac

Study Type: Interventional
Study Design: Prevention, Randomized
Official Title: The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: August 1996
Detailed Description:

OBJECTIVES:

  • Determine the response of the colonic epithelium in normal volunteers at average or above average risk of colon cancer, when given short term treatment with plant phenolics such as curcumin, rutin, and quercetin.
  • Compare the colonic mucosal response to the plant phenolics with their response to sulindac in order to evaluate whether they share common mechanisms for colon cancer chemoprevention.
  • Determine the lowest optimal dose for each of the three plant phenolics that is effective in modulating biomarkers of colon epithelial cell turnover and, therefore, potentially inhibiting colon cancer development.
  • Assess the response of the colonic epithelium to curcumin in volunteers at average risk of colon cancer development.

OUTLINE: This is a randomized, controlled, two part, single institution study. Patients in Part B are randomized by gender.

All patients undergo flexible sigmoidoscopic exam.

  • Part A: Patients, in cohorts of 5-10, receive one of the following five treatments in addition to the control diet: nothing (arm I), oral sulindac twice a day (arm II), oral rutin at 1 of 3 doses twice a day (arms III, IV, and V), oral quercetin at 1 of 3 doses twice a day (arms V, VI, and VII), or at 1 of 3 doses oral curcumin twice a day (arms VIII, IX, and X). Patients are first randomized to the highest doses of rutin, quercetin, and curcumin and then lower doses may be given in order to determine the minimally effective dose. Treatment is continued for 6-10 weeks.
  • Part B: Patients are randomized to receive the control diet only (arm I) or the control diet plus oral curcumin twice a day (arm II) for 6-10 weeks. Patients are followed every 2 weeks.

PROJECTED ACCRUAL: There will be 130 patients (110 in Part A and 20 in Part B) accrued into this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Individuals at average risk (Parts A and B) or above average risk (Part A only) for development of colon cancer

    • Average risk individuals defined as:

      • No history of colon adenomas
      • No strong family history of colon polyps or cancer
    • Above average risk individuals defined as:

      • History of one or more sporadic adenomatous polyps at least 0.5 cm in size (either tubular, tubulovillous, or villous adenomas)
      • Have had polypectomy or refused this procedure
      • No significant family history of adenomatous polyps, colon cancer, or hereditary nonpolyposis colorectal cancer or other hereditary colon cancer syndrome
      • Polyps should not have had a focus of adenocarcinoma within them
  • No history of gastrointestinal cancer outside of the large bowel
  • No other gastrointestinal mucosal epithelial disease (e.g., Barrett's esophagus, chronic or recurrent peptic ulcer disease, celiac sprue, or other disorders of nutrient absorption)
  • No significant asymptomatic lesions on flexible sigmoidoscopy, such as inflammation, premalignancy or malignancy

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • No platelet or coagulation abnormalities
  • No personal or family history of a bleeding disorder
  • Hematopoietic concentration must not be due to significant acute or chronic disorder

Hepatic:

  • No liver disease

Renal:

  • No renal insufficiency

Cardiovascular:

  • No uncontrolled hypertension
  • No chronic congestive heart failure
  • No history of endocarditis
  • No history of rheumatic fever
  • No cardiac valve prostheses
  • No mitral valve prolapse that requires antibiotic prophylaxis

Other:

  • HIV negative
  • No gout
  • No pancreatitis
  • No other chronic viral infection
  • No significant acute or uncontrolled chronic medical illness
  • Generally non-smoking (no more than 4 cigarettes per week, i.e., not daily smokers)
  • Must abstain from smoking for at least 1 month prior to enrolling in the study
  • No alcohol consumption of greater than 2 glasses of wine or beer per day
  • Normal weight (90-120% of optimum body weight) and body habitus
  • No change in weight within 5-10% of body weight within the past year
  • No history of inflammatory bowel disease (either ulcerative colitis or Crohn's disease )
  • No hearing or equilibrium disorders
  • No other prior malignancy except resected carcinoma in situ of the cervix or nonmelanoma skin cancer
  • No allergies to sulindac or tartrazine dyes or prior severe adverse reactions to nonsteroidal antiinflammatory drugs (asthma, gastrointestinal bleeding, or renal insufficiency)
  • No potential allergy to curcumin, quercetin, or rutin
  • No gastrointestinal bleeding
  • Not institutionalized, mentally disabled, or incarcerated
  • No unusually high intake of stored micronutrients or high doses of supplemental calcium or folate
  • Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • No concurrent coumadin
  • No chronic use of nonsteroidal antiinflammatory drugs (unless they can be stopped for 3 months)
  • No other putative colon cancer chemoprevention agents (unless they can be stopped for 3 months)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003365

Locations
United States, New York
Rockefeller University Hospital
New York, New York, United States, 10021-6399
Sponsors and Collaborators
Rockefeller University
Investigators
Study Chair: Steven J. Shiff, MD Cancer Institute of New Jersey
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000066350, RUH-SSH-190-0600, RUH-SSH-190-0698, NCI-V98-1425
Study First Received: November 1, 1999
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00003365     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
colon cancer

Study placed in the following topic categories:
Anti-Inflammatory Agents
Digestive System Neoplasms
Curcumin
Antioxidants
Gastrointestinal Diseases
Cyclooxygenase Inhibitors
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Intestinal Neoplasms
Digestive System Diseases
Analgesics, Non-Narcotic
Gastrointestinal Neoplasms
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Sulindac
Antirheumatic Agents
Quercetin
Colorectal Neoplasms

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Antineoplastic Agents
Colonic Diseases
Physiological Effects of Drugs
Rectal Diseases
Neoplasms by Site
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Digestive System Neoplasms
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Intestinal Diseases
Protective Agents
Intestinal Neoplasms
Pharmacologic Actions
Neoplasms
Digestive System Diseases
Analgesics, Non-Narcotic
Gastrointestinal Neoplasms
Peripheral Nervous System Agents
Sulindac
Antirheumatic Agents
Central Nervous System Agents
Quercetin
Colorectal Neoplasms

ClinicalTrials.gov processed this record on September 02, 2009